Tirosyne Kinase Inhibithors (TKIs) in the Treatment of Non –Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
Abstract
Tyrosine Kinase Inhibitors are new drugs developed in the last decade. For Non-Small Cell Lung Cancer this drug brought more hope for patients with this disease. Also TKIs are better tolerated then chemotherapy. The efficacy of TKIs is dependent of the presence of Epidermal Grows Factor Receptor gene mutation. This mutation account for about 9% of patients with lung cancer in Europe. This short review try to give the minimal knowledge to clinicians, especially medical oncologists, about mechanism of action, pharmacokinetics of TKIs used in the treatment NSCLC.Keywords: Tyrosine Kinase Inhibitors (TKI); Non -Small Cell Lung Cancer; Pharmacokinetics aspects
Keywords:
Tyrosine Kinase Inhibitors, Non -Small Cell Lung Cancer, Pharmacokinetics aspectsDOI
https://doi.org/10.22270/jddt.v10i1.3830References
https://www.wcrf.org/dietandcancer/cancer-trends/lung-cancer-statistics
https://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor
https://www.who.int/cancer/country.../rou_en.pdf
Ciardiello, F. and Tortora, G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160–1174
Foluso Ogunleye, MD; Mohammed Ibrahim, MD; Michael Stender, MD; Gregory Kalemkerian, MD; Ishmael Jaiyesimi, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer A paradigm shift in stage IV non-small cell lung cancer treatment
Kitagawa D, Yokota K, Gouda M, et al. Activity-based kinase profiling ofapproved tyrosine kinase inhibitors. Genes Cells 2013;18:110–22.
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2inhibitor highly effective in preclinical lung cancer models. Oncogene2008;27:4702–11.
Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activityof afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol ExpTher 2012;343:342–50.
Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2mutations that are resistant to gefitinib. Cancer Res 2007;67:11924–32.
Solange Petersa, Stefan Zimmermanna, Alex A. Adjeib, Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014 Sep;40(8):917-26. doi: 10.1016/j.ctrv.2014.06.010.
Niels Eckstein, Lea Röper, Bodo Haas, Henrike Potthast, Ulrike Hermes, Christoph Unkrig,1 Frauke Naumann-Winter,1 and Harald Enzmann1, Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective, doi: 10.1186/1756-9966-33-15, J Exp Clin Cancer Res. 2014; 33(1): 15.
Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers, Clin Pharmacokinet, 40 (2001), 297-306
Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of European Medicines Agency. Iressa (gefitinib) Assessment Report, July 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001016/WC500036361.pdf 20 02 2014.
Frohna P, Lu J, Eppler S, et al.Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects,J Clin Pharmacol, 46 (2006), pp. 282-290
Boehringer Ingelheim. Gilotrif [prescribing information] (2014) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. http://www.gilotrif.com/. 17 05 2014.
Giri N, LaBadie RR, Liang Y, et al. Absolute bioavailability of dacomitinib (PF-00299804): Comparison of oral and intravenous administration in healthy volunteers. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5–9; San Diego, CA. Philadelphia (PA): Abstract CT208.
Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors, Clin Cancer Res, 17 (2011), 1131-1139
Ruiz-Garcia A, Masters JC, LaBadie RR, et al.Effect of food and antacid treatment on bioavailability of 45 mg tablet of dacomitinib relative to dacomitinib administration under fasted conditions (abstract PII-007),Clin Pharmacol Ther, 95 (2014), S63
European Medicines Agency. Giotrif. Summary of Product Characteristics, 16 October 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002280/WC500152392.pdf. 20 02 2014].
Bello, C.L., Smith, E., Ruiz-Garcia, A. et al. A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemother Pharmacol. 2013; 72: 379–385
Lu, J.F., Eppler, S.M., Wolf, J. et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006; 80: 136–145|
Schnell D, Buschke S, Fuchs H, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol 2014;Jun 7. [Epub ahead of print].
D. McKillop, A.D. McCormick, A. Millar, et al.Cytochrome P450-dependent metabolism of gefitinib Xenobiotica, 35 (2005), 39-50
H.C. Swaisland, R.P. Smith, A. Laight, et al.Single-dose clinical pharmacokinetic studies of gefitinib, Clin Pharmacokinet, 44 (2005),1165-1177
J. Ling, K.A. Johnson, Z. Miao, et al.Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers Drug Metab Dispos, 34 (2006),420-426
Li J, Zhao M, He P, Hidalgo M, Baker SD, Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes, Clin Cancer Res, 13 (2007) 3731-3737
Hamilton M, Wolf JL, Rusk J, et al.Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res, 12 (2006), 2166-2171
Bello CL, Smith E, Ruiz-Garcia A, et al.A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers Cancer Chemother Pharmacol, 72 (2013),379-385
Stopfer P, Marzin K, Narjes H, et al.Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers Cancer Chemother Pharmacol, 69 (2012), pp. 1051-1061
Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS1, Mann H, So K, Johnson M, Vishwanathan K. Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. J Pharmacol Exp Ther. 2019 May;369(2):291-299. doi: 10.1124/jpet.118.255919. Epub 2019 Mar 14.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf
Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 2015;26:1421-7. 10.1093/annonc/mdv186
De Grève J, Moran T, Graas MP, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 2015;88:63-9. 10.1016/j.lungcan.2015.01.013
De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123-7. 10.1016/j.lungcan.2012.01.008
Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase IIB, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89. 10.1016/S1470-2045(16)30033-X
Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1454-66. 10.1016/S1470-2045(17)30608-3
Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61. 10.1158/2159-8290.CD-14-0337
Published
Abstract Display: 545 
PDF Downloads: 866 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.